4516 heads into the final week of June with an interesting split between its worsening price trend and a valuation picture that keeps getting cheaper.
The stock's month-long drift is the central story. Shares closed at ¥3,972 on June 19, down 6.3% over the past month, trimming a modest 0.7% weekly recovery. That slide has pushed the price-to-book ratio to 0.88x — the stock now trades below its own net asset value. EV/EBITDA has compressed to 5.5x, down meaningfully over 30 days. Analyst consensus, last updated in late May, implies a mean price target of ¥5,514 — a 39% premium to where shares trade today. That gap has been widening as the stock drifts lower, and the factor scoring reflects it: the EV/EBIT rank scores in the 85th percentile of the ORTEX universe, placing Nippon Shinyaku firmly in the cheap end of the pharma peer set.
The lending market offers no drama here — and that absence of tension is itself noteworthy. Borrow availability is essentially unconstrained, with the availability reading pegged at the ceiling of the tracked range and over 67 million shares sitting idle in the lending pool. Less than 0.2% of available stock is currently lent out, the lowest utilisation reading in three months. Cost to borrow has eased 8% on the week to just 0.88%, well within its narrow 12-month trading band of roughly 0.8%–1.1%. Short sellers are simply not interested in this name: the short score of 30.1 ranks in the 79th percentile for short pressure but the underlying activity is minimal. The borrow market reads as completely uncontested.
Institutional ownership is stable and largely domestic. Meiji Yasuda Life holds the biggest stake at 9.6%, followed by Nomura Asset Management at 6.1%. Neither has recently changed position. The marginal movers on the shareholder list are international passive names — BlackRock added around 30,700 shares as of May 31, Dimensional Fund Advisors picked up 42,300. These are systematic index-driven flows rather than conviction signals, but they do point to a base of sticky, long-only holders underpinning the register.
Among correlated TSE peers, the picture this week is mixed. 4578 gained 3.1% on the week while 4553 slipped 1.7%, suggesting the sector is not moving as a cohort. 4890 was flat on the week before a sharp 3.9% single-day fall on Friday — a reminder that idiosyncratic risk remains elevated across mid-cap Japanese pharma names. Nippon Shinyaku's next earnings event is flagged for August 7, and the most recent print in May produced a modest 2.5% one-day gain, consistent with the prior February result.
The August 7 result now becomes the clearest near-term reference point — specifically whether the widening gap between the current price and consensus targets reflects a genuine revaluation or simply a slow drift that upcoming earnings can resolve.
See the live data behind this article on ORTEX.
Open 4516 on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
